Page 2 - Read Online
P. 2
Topic: SBRT and
Immunotherapy for the
Management of HCC: A
Recent Appraisal
Guest Editor:
Jia Fan, MD
Hepatocellular carcinoma (HCC) is the most
Department of Liver Surgery and
Transplantation, Liver Cancer frequent primary liver cancer, leading to more
Institute, Zhongshan Hospital, Fudan than 700 thousand deaths annually. In recent
University, Shanghai, China. years, immunotherapy has emerged as a novel,
President of Shanghai Zhongshan effective systemic treatment for advanced HCC,
Hospital, Shanghai, China.
Academician of Chinese Academy of which can potentially suppress tumor recurrence
Sciences and metastasis. However, the objective response
rate of simply immunologic agent treatment for
HCC is still unsatisfactory. The combination of
conventional treatments including stereotactic
body radiation therapy (SBRT) with specific
immunotherapeutic approaches may dramatically
improve outcome of HCC patients. Moreover, the
advancement of SBRT techniques has allowed
for a safer administration of higher levels of dose
to liver cancer while minimizing the potential
Academic Editor: liver toxicities. In this edition of Hepatoma
Ying-Hong Shi, MD Research, we will discuss new advances in SBRT,
immunotherapy, and combined strategies for the
Department of Liver Surgery and
Transplantation, Liver Cancer treatment of patients with liver cancer.
Institute, Zhongshan Hospital, Fudan
University, Shanghai, China.
